UNBS5162

製品コードS8869 バッチS886901

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
化学式

C17H18N4O3
分子量 326.35 CAS No. 956590-23-1
Solubility (25°C)* 体外 DMSO 17 mg/mL (52.09 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 UNBS5162 is a pan-antagonist of CXCL chemokine expression with in vitro cytotoxic activity (IC50 range of 0.5-5 µM) against a range of human cancer cell lines including glioblastoma (Hs683 and U373MG), colorectal (HCT-15 and LoVo), non-small-cell lung (A549) and breast (MCF-7).
in vitro

Exposure of PC-3 cells to UNBS5162 (1 µM for 5 successive days) dramatically decreases the expression of the proangiogenic CXCL chemokines. UNBS5162 displays weak in vitro antiproliferative activity with IC50 values of 17.3 μM, 16 μM, 4.7 μM, 8.5 μM, 28.8 μM, 8.9 μM, 46.5 μM, 21.2 μM, 9.1 μM in PC-3, DU-145, U373-MG, Hs683, HCT-15, LoVo, MCF-7, A549 and Bx-PC-3 cells. At 10 µM UNBS5162 markedly impairs PC-3 tumor cell growth kinetics, without inducing senescence, whereas the reverse feature is observed with respect to DU-145 cells. This difference might result from their respective p53 status and/or the extent of p16 expression. At 1 µM, UNBS5162 induces no such antitumor effects. UNBS5162 at 10 µM markedly increased the levels of heterochromatin in PC-3 cells through an increase in number of histones, at least at the mRNA levels[1]. UNBS5162 has been identified to decrease levels of CXC chemokine ligand (CXCL) chemokines, including CXCL1, CXCL5 and CXCL8, in experimental prostate cancer and has a good inhibitory effect on the proliferation of tumour cells in vitro and in vivo. It inhibits cell proliferation, invasion and migration, and promote cell apoptosis, potentially through the PI3K/AKT signalling pathway in SKOV3 ovarian cancer cells[2].
in vivo

In vivo UNBS5162 after repeat administration significantly increases survival in orthotopic human prostate cancer models. In female mice for testing the pharmacokinetic profiles of UNBS5162, Systemic exposure after oral administration of 80 mg/kg is relatively low (Cmax = 510 ng/ml and AUC0-∞ = 886 ng·h/ml) reflected in an absolute bioavailability calculated to be only 3.84%. The volume of distribution (Vd) and the total clearance are estimated to be 18.9 L/kg and 3.47 L/h per kilogram, respectively. The half-life after i.v. administration of 20-mg/kg UNBS5162 is estimated to be 3.8 hours. Post-i.v. UNBS5162 plasma levels of 10 µM are only maintained for approximately 30 minutes, whereas 1-µM levels are sustained for maximally 2 hours[1].

プロトコル(参考用のみ)

細胞アッセイ 細胞株 PC-3 and DU- 145 cells
濃度 10 µM
反応時間 72 h
実験の流れ

--
動物実験 動物モデル Female B6D2F1 mouse
投薬量 20 mg/kg (iv) or 80 mg/kg (oral)
投与方法 i.v. bolus injection or oral administration

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Metformin potentiates nephrotoxicity by promoting NETosis in response to renal ferroptosis [ Cell Discov, 2023, 9(1):104] PubMed: 37848438
Metformin potentiates nephrotoxicity by promoting NETosis in response to renal ferroptosis [ Cell Discov, 2023, 9(1):104] PubMed: 37848438

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。